Original Article

You have full text access to this OnlineOpen article

Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma

A Phase II trial using a triplet combination

  1. Swan-Swan Leong M.D.1,†,*,
  2. Joseph Wee M.D.2,
  3. Miah Hiang Tay M.D.1,
  4. Chee Keong Toh M.D.1,
  5. Say Beng Tan Ph.D.3,
  6. Choon Hua Thng M.D.4,
  7. Kian Fong Foo M.D.1,
  8. Wan Teck Lim M.D.1,
  9. Terence Tan M.D.2,
  10. Eng Huat Tan M.D.1

Article first published online: 20 DEC 2004

DOI: 10.1002/cncr.20804

Issue

Cancer

Cancer

Volume 103, Issue 3, pages 569–575, 1 February 2005

Additional Information

How to Cite

Leong, S.-S., Wee, J., Tay, M. H., Toh, C. K., Tan, S. B., Thng, C. H., Foo, K. F., Lim, W. T., Tan, T. and Tan, E. H. (2005), Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma. Cancer, 103: 569–575. doi: 10.1002/cncr.20804

Author Information

  1. 1

    Department of Medical Oncology, National Cancer Center, Singapore

  2. 2

    Department of Therapeutic Radiology, National Cancer Center, Singapore

  3. 3

    Department of Clinical Trials & Epidemiology, National Cancer Center, Singapore

  4. 4

    Department of Radiology, National Cancer Center, Singapore

  1. †

    Fax: (011) 65 62272759

*Department of Medical Oncology, National Cancer Center, 11 Hospital Drive, Singapore 169610

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 20 DEC 2004
  3. Manuscript Accepted: 13 OCT 2004
  4. Manuscript Revised: 15 SEP 2004
  5. Manuscript Received: 9 JUL 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (96K)

REFERENCES

  • 1
    Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 1310–1317.
  • 2
    Ong YK, Heng DM, Chung B, et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer. 2003; 39: 1535–1541.
  • 3
    Merlano M, Vitale V, Rosso R, et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 1992; 327: 1115–1121.
  • 4
    The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiotherapy compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324: 1685–1690.
  • 5
    Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. J Natl Cancer Inst. 1996; 88: 890–899.
  • 6
    Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol. 2000; 18: 2040–2045.
  • 7
    Chan AT, Teo PM, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995; 33: 569–577.
  • 8
    Au E, Ang PT. A Phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 1994; 5: 87–89.
  • 9
    Lin JC, Jan JS, Hsu CY. Outpatient weekly chemotherapy in patients with nasopharyngeal carcinoma and distant metastasis. Cancer. 1998; 83: 635–640.
    Direct Link:
  • 10
    Chi KH, Chang YC, Chan WK, et al. A Phase II study of carboplatin in nasopharyngeal carcinoma. Oncology. 1997; 54: 203–207.
  • 11
    Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol. 1998; 9: 327–329.
  • 12
    Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol. 2002; 13: 150–156.
  • 13
    Tan EH, Khoo KS, Wee J, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999; 10: 235–237.
  • 14
    Hainsworth JD, Burris HA, Erland JB, et al. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer. 1999; 85: 1269–1276.
    Direct Link:
  • 15
    Hansen SW. Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol. 2002; 29(Suppl 1): S17–S19.
  • 16
    Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365–376.
  • 17
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989; 7: 1748–1756.
  • 18
    Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41.
  • 19
    Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer. 1981; 47: 207–214.
    Direct Link:
  • 20
    Tan SB, Machin D. Bayesian two-stage designs for Phase II clinical trials. Stat Med. 2002; 21: 1991–2012.
    Direct Link:
  • 21
    Newcombe RG, Altman DG. Proportions and their differences. In: AltmanDG, MachinD, BryantTN, et al., editors. Statistics with confidence, 2nd ed. London: BMJ Books, 2000: 93–104.
  • 22
    Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual, 3rd ed. Brussels: EORTC, 2001.
  • 23
    Decker DA, Drehchman A, Al-Sarraf M, Crissman J, Reed ML. Chemotherapy of nasophatyngeal carcinoma. A ten year experience. Cancer. 1983; 52: 602–605.
    Direct Link:
  • 24
    McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M, Siu LL. A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2002; 38: 686–690.
  • 25
    Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a Phase II toxicity, response, and survival analysis. J Clin Oncol. 1995; 13: 1860–1870.
  • 26
    Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a Phase II trial. J Clin Oncol. 1996; 14: 2054–2060.
  • 27
    Glorieux P, Ortmanns P, Marien S, et al. Multi-center study of two dose levels of paclitaxel and carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC). Anticancer Res. 2001; 21: 1487–1494.
  • 28
    Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001; 19: 2527–2533.
  • 29
    Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, Kainz C. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity. Anticancer Res. 2000; 20: 4047–4050.
  • 30
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Neurotoxicity associated with a regimen of carboplatin (AUC 5–6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynaecologic malignancies. J Cancer Res Clin Oncol. 2001; 127: 55–58.
  • 31
    Leong SS, Tan EH, Fong KM, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable Stage III non-small-cell lung cancer. J Clin Oncol. 2003; 21: 1767–1774.
  • 32
    Cheong K, Li J, Karapetis CS. Gemcitabine and reactivation of hepatitis B. Med Oncol. 2003; 20: 385–388.
  • 33
    Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepatol. 2004; 11: 55–59.
    Direct Link:
  • 34
    Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125: 1742–1749.
  • 35
    Soh LT, Ang PT, Sng I, Chua EJ, Ong YW. Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer. 1992; 28A: 1338–1339.
  • 36
    Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000; 15: 1356–1361.
    Direct Link:
View Full Article (HTML) Get PDF (96K)